Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein, JD; Lutzko, C; Leemhuis, T; Zhu, X; Pham, G; Ray, L; Thomas, S; Dourson, C; Wilhelm, J; Lane, A; et al.
Blood Advances.
2022;
6:2897-2907.
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients.
Rubinstein, JD; Jodele, S; Heyenbruch, D; Wilhelm, J; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; Keller, M; et al.
Transplantation and cellular therapy.
2022;
28:116.e1-116.e7.
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
Rubinstein, JD; Zhu, X; Leemhuis, T; Pham, G; Ray, L; Emberesh, S; Jodele, S; Thomas, S; Cancelas, JA; Bollard, CM; et al.
Blood Advances.
2021;
5:3309-3321.
Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).
Niss, O; Lorsbach, RB; Berger, M; Chonat, S; McLemore, M; Buchbinder, D; McCavit, T; Shaffer, LG; Simpson, J; Schwartz, JH; et al.
Blood Cells, Molecules, and Diseases.
2021;
87.
The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation.
Laskin, BL; Denburg, MR; Furth, SL; Moatz, T; Altrich, M; Kleiboeker, S; Lutzko, C; Zhu, X; Blackard, JT; Jodele, S; et al.
Clinical Infectious Diseases.
2020;
71:3044-3054.
VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects.
Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al.
American Journal of Human Genetics.
2020;
107:1149-1156.
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.
Nelson, AS; Heyenbruch, D; Rubinstein, JD; Sabulski, A; Jodele, S; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; et al.
Blood Advances.
2020;
4:5745-5754.
Early Results from a Phase 1/2 Study of Aru-1801 Gene Therapy for Sickle Cell Disease (SCD): Manufacturing Process Enhancements Improve Efficacy of a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant.
Grimley, M; Asnani, M; Shrestha, A; Felker, S; Lutzko, C; Arumugam, PI; Witting, S; Knight-Madden, J; Niss, O; Quinn, CT; et al.
Blood.
2020;
136:20-21.